nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—liver cancer	0.595	0.788	CbGaD
Gliclazide—ALB—liver cancer	0.16	0.212	CbGaD
Gliclazide—Glipizide—PPARG—liver cancer	0.00091	0.845	CrCbGaD
Gliclazide—Dyspepsia—Sorafenib—liver cancer	0.000322	0.00261	CcSEcCtD
Gliclazide—Coma—Doxorubicin—liver cancer	0.000321	0.0026	CcSEcCtD
Gliclazide—Oesophagitis—Doxorubicin—liver cancer	0.000321	0.0026	CcSEcCtD
Gliclazide—Rash maculo-papular—Doxorubicin—liver cancer	0.000319	0.00258	CcSEcCtD
Gliclazide—Thrombophlebitis—Epirubicin—liver cancer	0.000318	0.00258	CcSEcCtD
Gliclazide—Neoplasm—Doxorubicin—liver cancer	0.000317	0.00257	CcSEcCtD
Gliclazide—Bladder pain—Doxorubicin—liver cancer	0.000317	0.00257	CcSEcCtD
Gliclazide—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.000316	0.00256	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Sorafenib—liver cancer	0.000316	0.00256	CcSEcCtD
Gliclazide—Fatigue—Sorafenib—liver cancer	0.000316	0.00256	CcSEcCtD
Gliclazide—Hepatic function abnormal—Epirubicin—liver cancer	0.000315	0.00255	CcSEcCtD
Gliclazide—Photosensitivity—Epirubicin—liver cancer	0.000313	0.00254	CcSEcCtD
Gliclazide—Constipation—Sorafenib—liver cancer	0.000313	0.00254	CcSEcCtD
Gliclazide—Pain—Sorafenib—liver cancer	0.000313	0.00254	CcSEcCtD
Gliclazide—Eczema—Epirubicin—liver cancer	0.000306	0.00248	CcSEcCtD
Gliclazide—Hepatic failure—Epirubicin—liver cancer	0.000306	0.00248	CcSEcCtD
Gliclazide—Abnormal vision—Doxorubicin—liver cancer	0.000306	0.00248	CcSEcCtD
Gliclazide—Mental disability—Doxorubicin—liver cancer	0.000304	0.00247	CcSEcCtD
Gliclazide—Gastrointestinal pain—Sorafenib—liver cancer	0.000299	0.00243	CcSEcCtD
Gliclazide—Renal failure acute—Epirubicin—liver cancer	0.000298	0.00242	CcSEcCtD
Gliclazide—Thrombophlebitis—Doxorubicin—liver cancer	0.000294	0.00238	CcSEcCtD
Gliclazide—Increased appetite—Epirubicin—liver cancer	0.000293	0.00237	CcSEcCtD
Gliclazide—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000293	0.00237	CcSEcCtD
Gliclazide—Hepatic function abnormal—Doxorubicin—liver cancer	0.000291	0.00236	CcSEcCtD
Gliclazide—Urticaria—Sorafenib—liver cancer	0.000291	0.00236	CcSEcCtD
Gliclazide—Photosensitivity—Doxorubicin—liver cancer	0.00029	0.00235	CcSEcCtD
Gliclazide—Body temperature increased—Sorafenib—liver cancer	0.000289	0.00234	CcSEcCtD
Gliclazide—Abdominal pain—Sorafenib—liver cancer	0.000289	0.00234	CcSEcCtD
Gliclazide—Renal impairment—Epirubicin—liver cancer	0.000289	0.00234	CcSEcCtD
Gliclazide—Hepatic failure—Doxorubicin—liver cancer	0.000283	0.0023	CcSEcCtD
Gliclazide—Eczema—Doxorubicin—liver cancer	0.000283	0.0023	CcSEcCtD
Gliclazide—Hypoglycaemia—Epirubicin—liver cancer	0.000282	0.00229	CcSEcCtD
Gliclazide—Cardiac failure—Epirubicin—liver cancer	0.000282	0.00229	CcSEcCtD
Gliclazide—Cerebrovascular accident—Epirubicin—liver cancer	0.000281	0.00228	CcSEcCtD
Gliclazide—Hyponatraemia—Epirubicin—liver cancer	0.000276	0.00224	CcSEcCtD
Gliclazide—Renal failure acute—Doxorubicin—liver cancer	0.000276	0.00224	CcSEcCtD
Gliclazide—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000275	0.00223	CcSEcCtD
Gliclazide—Pain in extremity—Epirubicin—liver cancer	0.000275	0.00223	CcSEcCtD
Gliclazide—Osteoarthritis—Epirubicin—liver cancer	0.000275	0.00223	CcSEcCtD
Gliclazide—Diplopia—Epirubicin—liver cancer	0.000275	0.00223	CcSEcCtD
Gliclazide—Increased appetite—Doxorubicin—liver cancer	0.000271	0.0022	CcSEcCtD
Gliclazide—Hypersensitivity—Sorafenib—liver cancer	0.00027	0.00219	CcSEcCtD
Gliclazide—Renal impairment—Doxorubicin—liver cancer	0.000268	0.00217	CcSEcCtD
Gliclazide—Asthenia—Sorafenib—liver cancer	0.000263	0.00213	CcSEcCtD
Gliclazide—Hypoglycaemia—Doxorubicin—liver cancer	0.000261	0.00211	CcSEcCtD
Gliclazide—Cardiac failure—Doxorubicin—liver cancer	0.000261	0.00211	CcSEcCtD
Gliclazide—Cerebrovascular accident—Doxorubicin—liver cancer	0.00026	0.00211	CcSEcCtD
Gliclazide—Pruritus—Sorafenib—liver cancer	0.000259	0.0021	CcSEcCtD
Gliclazide—Hyponatraemia—Doxorubicin—liver cancer	0.000256	0.00207	CcSEcCtD
Gliclazide—Osteoarthritis—Doxorubicin—liver cancer	0.000255	0.00206	CcSEcCtD
Gliclazide—Diplopia—Doxorubicin—liver cancer	0.000255	0.00206	CcSEcCtD
Gliclazide—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000255	0.00206	CcSEcCtD
Gliclazide—Pain in extremity—Doxorubicin—liver cancer	0.000255	0.00206	CcSEcCtD
Gliclazide—Dry skin—Epirubicin—liver cancer	0.000252	0.00204	CcSEcCtD
Gliclazide—Diarrhoea—Sorafenib—liver cancer	0.00025	0.00203	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000248	0.00201	CcSEcCtD
Gliclazide—Gastritis—Epirubicin—liver cancer	0.000244	0.00197	CcSEcCtD
Gliclazide—Dizziness—Sorafenib—liver cancer	0.000242	0.00196	CcSEcCtD
Gliclazide—Abdominal distension—Epirubicin—liver cancer	0.000239	0.00194	CcSEcCtD
Gliclazide—Asthma—Epirubicin—liver cancer	0.000238	0.00193	CcSEcCtD
Gliclazide—Dry skin—Doxorubicin—liver cancer	0.000233	0.00189	CcSEcCtD
Gliclazide—Vomiting—Sorafenib—liver cancer	0.000233	0.00189	CcSEcCtD
Gliclazide—Angina pectoris—Epirubicin—liver cancer	0.000232	0.00188	CcSEcCtD
Gliclazide—Rash—Sorafenib—liver cancer	0.000231	0.00187	CcSEcCtD
Gliclazide—Dermatitis—Sorafenib—liver cancer	0.000231	0.00187	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000229	0.00186	CcSEcCtD
Gliclazide—Headache—Sorafenib—liver cancer	0.000229	0.00186	CcSEcCtD
Gliclazide—Bronchitis—Epirubicin—liver cancer	0.000229	0.00185	CcSEcCtD
Gliclazide—Pancytopenia—Epirubicin—liver cancer	0.000226	0.00183	CcSEcCtD
Gliclazide—Gastritis—Doxorubicin—liver cancer	0.000225	0.00183	CcSEcCtD
Gliclazide—Abdominal distension—Doxorubicin—liver cancer	0.000222	0.0018	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Epirubicin—liver cancer	0.000221	0.00179	CcSEcCtD
Gliclazide—Asthma—Doxorubicin—liver cancer	0.00022	0.00178	CcSEcCtD
Gliclazide—Nausea—Sorafenib—liver cancer	0.000217	0.00176	CcSEcCtD
Gliclazide—Photosensitivity reaction—Epirubicin—liver cancer	0.000217	0.00176	CcSEcCtD
Gliclazide—Weight increased—Epirubicin—liver cancer	0.000216	0.00175	CcSEcCtD
Gliclazide—Hyperglycaemia—Epirubicin—liver cancer	0.000215	0.00174	CcSEcCtD
Gliclazide—Angina pectoris—Doxorubicin—liver cancer	0.000214	0.00174	CcSEcCtD
Gliclazide—Pneumonia—Epirubicin—liver cancer	0.000213	0.00173	CcSEcCtD
Gliclazide—Drowsiness—Epirubicin—liver cancer	0.000212	0.00172	CcSEcCtD
Gliclazide—Bronchitis—Doxorubicin—liver cancer	0.000212	0.00172	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00021	0.0017	CcSEcCtD
Gliclazide—Pancytopenia—Doxorubicin—liver cancer	0.000209	0.00169	CcSEcCtD
Gliclazide—Renal failure—Epirubicin—liver cancer	0.000208	0.00169	CcSEcCtD
Gliclazide—Neuropathy peripheral—Epirubicin—liver cancer	0.000208	0.00168	CcSEcCtD
Gliclazide—Jaundice—Epirubicin—liver cancer	0.000207	0.00168	CcSEcCtD
Gliclazide—Conjunctivitis—Epirubicin—liver cancer	0.000206	0.00167	CcSEcCtD
Gliclazide—Urinary tract infection—Epirubicin—liver cancer	0.000206	0.00167	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000205	0.00166	CcSEcCtD
Gliclazide—Sweating—Epirubicin—liver cancer	0.000203	0.00165	CcSEcCtD
Gliclazide—Photosensitivity reaction—Doxorubicin—liver cancer	0.000201	0.00163	CcSEcCtD
Gliclazide—Hepatobiliary disease—Epirubicin—liver cancer	0.000201	0.00163	CcSEcCtD
Gliclazide—Weight increased—Doxorubicin—liver cancer	0.0002	0.00162	CcSEcCtD
Gliclazide—Epistaxis—Epirubicin—liver cancer	0.0002	0.00162	CcSEcCtD
Gliclazide—Sinusitis—Epirubicin—liver cancer	0.000199	0.00161	CcSEcCtD
Gliclazide—Hyperglycaemia—Doxorubicin—liver cancer	0.000199	0.00161	CcSEcCtD
Gliclazide—Agranulocytosis—Epirubicin—liver cancer	0.000198	0.0016	CcSEcCtD
Gliclazide—Pneumonia—Doxorubicin—liver cancer	0.000197	0.0016	CcSEcCtD
Gliclazide—Drowsiness—Doxorubicin—liver cancer	0.000196	0.00159	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000195	0.00158	CcSEcCtD
Gliclazide—Bradycardia—Epirubicin—liver cancer	0.000194	0.00157	CcSEcCtD
Gliclazide—Renal failure—Doxorubicin—liver cancer	0.000193	0.00156	CcSEcCtD
Gliclazide—Neuropathy peripheral—Doxorubicin—liver cancer	0.000192	0.00156	CcSEcCtD
Gliclazide—Jaundice—Doxorubicin—liver cancer	0.000191	0.00155	CcSEcCtD
Gliclazide—Rhinitis—Epirubicin—liver cancer	0.000191	0.00155	CcSEcCtD
Gliclazide—Conjunctivitis—Doxorubicin—liver cancer	0.000191	0.00155	CcSEcCtD
Gliclazide—Urinary tract infection—Doxorubicin—liver cancer	0.000191	0.00155	CcSEcCtD
Gliclazide—Hepatitis—Epirubicin—liver cancer	0.00019	0.00154	CcSEcCtD
Gliclazide—Hypoaesthesia—Epirubicin—liver cancer	0.000189	0.00154	CcSEcCtD
Gliclazide—Pharyngitis—Epirubicin—liver cancer	0.000189	0.00153	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—liver cancer	0.000188	0.00152	CcSEcCtD
Gliclazide—Oedema peripheral—Epirubicin—liver cancer	0.000188	0.00152	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—liver cancer	0.000186	0.0015	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—liver cancer	0.000185	0.0015	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—liver cancer	0.000184	0.00149	CcSEcCtD
Gliclazide—Visual impairment—Epirubicin—liver cancer	0.000183	0.00149	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—liver cancer	0.000183	0.00148	CcSEcCtD
Gliclazide—Erythema multiforme—Epirubicin—liver cancer	0.00018	0.00146	CcSEcCtD
Gliclazide—Bradycardia—Doxorubicin—liver cancer	0.000179	0.00145	CcSEcCtD
Gliclazide—Eye disorder—Epirubicin—liver cancer	0.000178	0.00144	CcSEcCtD
Gliclazide—Tinnitus—Epirubicin—liver cancer	0.000178	0.00144	CcSEcCtD
Gliclazide—Flushing—Epirubicin—liver cancer	0.000177	0.00143	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—liver cancer	0.000177	0.00143	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—liver cancer	0.000176	0.00143	CcSEcCtD
Gliclazide—Hypoaesthesia—Doxorubicin—liver cancer	0.000175	0.00142	CcSEcCtD
Gliclazide—Pharyngitis—Doxorubicin—liver cancer	0.000175	0.00142	CcSEcCtD
Gliclazide—Oedema peripheral—Doxorubicin—liver cancer	0.000174	0.00141	CcSEcCtD
Gliclazide—Chills—Epirubicin—liver cancer	0.000171	0.00138	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—liver cancer	0.00017	0.00138	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—liver cancer	0.00017	0.00138	CcSEcCtD
Gliclazide—Glyburide—ALB—liver cancer	0.000167	0.155	CrCbGaD
Gliclazide—Mental disorder—Epirubicin—liver cancer	0.000167	0.00135	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—liver cancer	0.000167	0.00135	CcSEcCtD
Gliclazide—Erythema—Epirubicin—liver cancer	0.000166	0.00134	CcSEcCtD
Gliclazide—Malnutrition—Epirubicin—liver cancer	0.000166	0.00134	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—liver cancer	0.000165	0.00133	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—liver cancer	0.000164	0.00133	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—liver cancer	0.000163	0.00132	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—liver cancer	0.000163	0.00132	CcSEcCtD
Gliclazide—Tension—Epirubicin—liver cancer	0.000163	0.00132	CcSEcCtD
Gliclazide—Nervousness—Epirubicin—liver cancer	0.000161	0.0013	CcSEcCtD
Gliclazide—Back pain—Epirubicin—liver cancer	0.00016	0.0013	CcSEcCtD
Gliclazide—Chills—Doxorubicin—liver cancer	0.000158	0.00128	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—liver cancer	0.000157	0.00128	CcSEcCtD
Gliclazide—Mental disorder—Doxorubicin—liver cancer	0.000154	0.00125	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—liver cancer	0.000154	0.00125	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—liver cancer	0.000153	0.00124	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—liver cancer	0.000153	0.00124	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—liver cancer	0.000153	0.00124	CcSEcCtD
Gliclazide—Agitation—Epirubicin—liver cancer	0.000152	0.00123	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—liver cancer	0.000151	0.00122	CcSEcCtD
Gliclazide—Tension—Doxorubicin—liver cancer	0.00015	0.00122	CcSEcCtD
Gliclazide—Malaise—Epirubicin—liver cancer	0.000149	0.00121	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—liver cancer	0.000149	0.00121	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—liver cancer	0.000148	0.0012	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—liver cancer	0.000148	0.0012	CcSEcCtD
Gliclazide—Palpitations—Epirubicin—liver cancer	0.000146	0.00119	CcSEcCtD
Gliclazide—Loss of consciousness—Epirubicin—liver cancer	0.000146	0.00118	CcSEcCtD
Gliclazide—Cough—Epirubicin—liver cancer	0.000145	0.00117	CcSEcCtD
Gliclazide—Convulsion—Epirubicin—liver cancer	0.000144	0.00116	CcSEcCtD
Gliclazide—Hypertension—Epirubicin—liver cancer	0.000143	0.00116	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—liver cancer	0.000142	0.00115	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—liver cancer	0.000142	0.00115	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—liver cancer	0.000141	0.00114	CcSEcCtD
Gliclazide—Chest pain—Epirubicin—liver cancer	0.000141	0.00114	CcSEcCtD
Gliclazide—Arthralgia—Epirubicin—liver cancer	0.000141	0.00114	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—liver cancer	0.000141	0.00114	CcSEcCtD
Gliclazide—Anxiety—Epirubicin—liver cancer	0.000141	0.00114	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00014	0.00114	CcSEcCtD
Gliclazide—Discomfort—Epirubicin—liver cancer	0.000139	0.00113	CcSEcCtD
Gliclazide—Malaise—Doxorubicin—liver cancer	0.000138	0.00112	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—liver cancer	0.000138	0.00112	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—liver cancer	0.000137	0.00111	CcSEcCtD
Gliclazide—Confusional state—Epirubicin—liver cancer	0.000136	0.00111	CcSEcCtD
Gliclazide—Palpitations—Doxorubicin—liver cancer	0.000136	0.0011	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—liver cancer	0.000135	0.00109	CcSEcCtD
Gliclazide—Infection—Epirubicin—liver cancer	0.000134	0.00109	CcSEcCtD
Gliclazide—Cough—Doxorubicin—liver cancer	0.000134	0.00108	CcSEcCtD
Gliclazide—Convulsion—Doxorubicin—liver cancer	0.000133	0.00108	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—liver cancer	0.000133	0.00107	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—liver cancer	0.000132	0.00107	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—liver cancer	0.000132	0.00107	CcSEcCtD
Gliclazide—Tachycardia—Epirubicin—liver cancer	0.000132	0.00107	CcSEcCtD
Gliclazide—Skin disorder—Epirubicin—liver cancer	0.000131	0.00106	CcSEcCtD
Gliclazide—Hyperhidrosis—Epirubicin—liver cancer	0.000131	0.00106	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—liver cancer	0.000131	0.00106	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—liver cancer	0.000131	0.00106	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—liver cancer	0.000131	0.00106	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—liver cancer	0.00013	0.00105	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00013	0.00105	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—liver cancer	0.000129	0.00105	CcSEcCtD
Gliclazide—Dry mouth—Doxorubicin—liver cancer	0.000128	0.00103	CcSEcCtD
Gliclazide—Hypotension—Epirubicin—liver cancer	0.000126	0.00102	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—liver cancer	0.000126	0.00102	CcSEcCtD
Gliclazide—Infection—Doxorubicin—liver cancer	0.000124	0.00101	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000123	0.000999	CcSEcCtD
Gliclazide—Nervous system disorder—Doxorubicin—liver cancer	0.000123	0.000995	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—liver cancer	0.000123	0.000993	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—liver cancer	0.000122	0.000991	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—liver cancer	0.000122	0.00099	CcSEcCtD
Gliclazide—Skin disorder—Doxorubicin—liver cancer	0.000122	0.000985	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—liver cancer	0.000121	0.000984	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—liver cancer	0.000121	0.00098	CcSEcCtD
Gliclazide—Dyspnoea—Epirubicin—liver cancer	0.000121	0.000977	CcSEcCtD
Gliclazide—Somnolence—Epirubicin—liver cancer	0.00012	0.000974	CcSEcCtD
Gliclazide—Dyspepsia—Epirubicin—liver cancer	0.000119	0.000965	CcSEcCtD
Gliclazide—Hypotension—Doxorubicin—liver cancer	0.000117	0.000948	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Epirubicin—liver cancer	0.000117	0.000946	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—liver cancer	0.000117	0.000945	CcSEcCtD
Gliclazide—Pain—Epirubicin—liver cancer	0.000116	0.000937	CcSEcCtD
Gliclazide—Constipation—Epirubicin—liver cancer	0.000116	0.000937	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000114	0.000924	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—liver cancer	0.000113	0.000917	CcSEcCtD
Gliclazide—Paraesthesia—Doxorubicin—liver cancer	0.000112	0.000911	CcSEcCtD
Gliclazide—Dyspnoea—Doxorubicin—liver cancer	0.000112	0.000904	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—liver cancer	0.000111	0.000903	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—liver cancer	0.000111	0.000902	CcSEcCtD
Gliclazide—Gastrointestinal pain—Epirubicin—liver cancer	0.000111	0.000896	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—liver cancer	0.00011	0.000893	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000108	0.000876	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—liver cancer	0.000108	0.000874	CcSEcCtD
Gliclazide—Urticaria—Epirubicin—liver cancer	0.000107	0.000871	CcSEcCtD
Gliclazide—Pain—Doxorubicin—liver cancer	0.000107	0.000867	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—liver cancer	0.000107	0.000867	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—liver cancer	0.000107	0.000867	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—liver cancer	0.000107	0.000867	CcSEcCtD
Gliclazide—Feeling abnormal—Doxorubicin—liver cancer	0.000103	0.000836	CcSEcCtD
Gliclazide—Gastrointestinal pain—Doxorubicin—liver cancer	0.000102	0.000829	CcSEcCtD
Gliclazide—Hypersensitivity—Epirubicin—liver cancer	9.97e-05	0.000808	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—liver cancer	9.94e-05	0.000806	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—liver cancer	9.89e-05	0.000802	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—liver cancer	9.89e-05	0.000802	CcSEcCtD
Gliclazide—Asthenia—Epirubicin—liver cancer	9.71e-05	0.000786	CcSEcCtD
Gliclazide—Pruritus—Epirubicin—liver cancer	9.57e-05	0.000776	CcSEcCtD
Gliclazide—Diarrhoea—Epirubicin—liver cancer	9.26e-05	0.00075	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—liver cancer	9.22e-05	0.000747	CcSEcCtD
Gliclazide—Asthenia—Doxorubicin—liver cancer	8.98e-05	0.000728	CcSEcCtD
Gliclazide—Dizziness—Epirubicin—liver cancer	8.94e-05	0.000725	CcSEcCtD
Gliclazide—Pruritus—Doxorubicin—liver cancer	8.86e-05	0.000718	CcSEcCtD
Gliclazide—Vomiting—Epirubicin—liver cancer	8.6e-05	0.000697	CcSEcCtD
Gliclazide—Diarrhoea—Doxorubicin—liver cancer	8.56e-05	0.000694	CcSEcCtD
Gliclazide—Rash—Epirubicin—liver cancer	8.53e-05	0.000691	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—liver cancer	8.52e-05	0.000691	CcSEcCtD
Gliclazide—Headache—Epirubicin—liver cancer	8.47e-05	0.000687	CcSEcCtD
Gliclazide—Dizziness—Doxorubicin—liver cancer	8.28e-05	0.000671	CcSEcCtD
Gliclazide—Nausea—Epirubicin—liver cancer	8.03e-05	0.000651	CcSEcCtD
Gliclazide—Vomiting—Doxorubicin—liver cancer	7.96e-05	0.000645	CcSEcCtD
Gliclazide—Rash—Doxorubicin—liver cancer	7.89e-05	0.000639	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—liver cancer	7.88e-05	0.000639	CcSEcCtD
Gliclazide—Headache—Doxorubicin—liver cancer	7.84e-05	0.000635	CcSEcCtD
Gliclazide—Nausea—Doxorubicin—liver cancer	7.43e-05	0.000602	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—F2—liver cancer	3.79e-05	0.000313	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TAT—liver cancer	3.77e-05	0.000312	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL2—liver cancer	3.72e-05	0.000308	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GGT1—liver cancer	3.71e-05	0.000308	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GOT1—liver cancer	3.71e-05	0.000308	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ADAM17—liver cancer	3.71e-05	0.000307	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	3.71e-05	0.000307	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—IL6—liver cancer	3.68e-05	0.000305	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CTNNB1—liver cancer	3.66e-05	0.000303	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CG—liver cancer	3.62e-05	0.0003	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP9—liver cancer	3.59e-05	0.000297	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—EPT1—liver cancer	3.57e-05	0.000295	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PSMD10—liver cancer	3.49e-05	0.000289	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PSMA4—liver cancer	3.49e-05	0.000289	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	3.47e-05	0.000287	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—UGDH—liver cancer	3.46e-05	0.000286	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTP1—liver cancer	3.44e-05	0.000285	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—HMOX1—liver cancer	3.39e-05	0.000281	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TAT—liver cancer	3.38e-05	0.00028	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTP1—liver cancer	3.34e-05	0.000276	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	3.33e-05	0.000275	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—HMOX1—liver cancer	3.29e-05	0.000272	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—HRAS—liver cancer	3.27e-05	0.00027	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—EPT1—liver cancer	3.25e-05	0.000269	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—STAT3—liver cancer	3.19e-05	0.000264	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CD—liver cancer	3.18e-05	0.000264	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IFNA1—liver cancer	3.18e-05	0.000263	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTM1—liver cancer	3.16e-05	0.000262	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SERPINE1—liver cancer	3.15e-05	0.000261	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL6—liver cancer	3.13e-05	0.000259	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—IL6—liver cancer	3.13e-05	0.000259	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TAT—liver cancer	3.08e-05	0.000255	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTM1—liver cancer	3.07e-05	0.000254	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	3.03e-05	0.000251	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP1A1—liver cancer	3e-05	0.000248	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TGFB1—liver cancer	2.96e-05	0.000245	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP1A1—liver cancer	2.91e-05	0.000241	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TGFB1—liver cancer	2.9e-05	0.00024	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—RAF1—liver cancer	2.84e-05	0.000235	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PRKCE—liver cancer	2.81e-05	0.000233	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—MTHFR—liver cancer	2.79e-05	0.000231	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CB—liver cancer	2.78e-05	0.00023	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—GGT1—liver cancer	2.77e-05	0.00023	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—TNF—liver cancer	2.76e-05	0.000229	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KRAS—liver cancer	2.74e-05	0.000227	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPARA—liver cancer	2.74e-05	0.000227	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—MTHFR—liver cancer	2.71e-05	0.000224	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PRKCE—liver cancer	2.7e-05	0.000224	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KRAS—liver cancer	2.69e-05	0.000223	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—CYCS—liver cancer	2.69e-05	0.000222	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—ABL1—liver cancer	2.67e-05	0.000221	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IGF2—liver cancer	2.66e-05	0.00022	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPARA—liver cancer	2.66e-05	0.00022	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CPT1B—liver cancer	2.56e-05	0.000212	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GLUL—liver cancer	2.56e-05	0.000212	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF2—liver cancer	2.56e-05	0.000212	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2—liver cancer	2.55e-05	0.000211	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HGF—liver cancer	2.51e-05	0.000208	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—GGT1—liver cancer	2.49e-05	0.000206	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—CSF2—liver cancer	2.49e-05	0.000206	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CA—liver cancer	2.47e-05	0.000205	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NR1H4—liver cancer	2.47e-05	0.000204	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTA3—liver cancer	2.43e-05	0.000201	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—liver cancer	2.39e-05	0.000198	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CSF2—liver cancer	2.39e-05	0.000198	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—H2AFX—liver cancer	2.35e-05	0.000195	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CG—liver cancer	2.35e-05	0.000194	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—HMOX1—liver cancer	2.34e-05	0.000193	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—liver cancer	2.33e-05	0.000193	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CPT1B—liver cancer	2.3e-05	0.00019	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GLUL—liver cancer	2.3e-05	0.00019	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—liver cancer	2.29e-05	0.000189	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CG—liver cancer	2.28e-05	0.000188	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	2.27e-05	0.000188	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPARG—liver cancer	2.27e-05	0.000188	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—liver cancer	2.23e-05	0.000185	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTA4—liver cancer	2.22e-05	0.000184	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NR1H4—liver cancer	2.22e-05	0.000184	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPARG—liver cancer	2.2e-05	0.000182	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTA3—liver cancer	2.18e-05	0.00018	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	2.17e-05	0.00018	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—liver cancer	2.17e-05	0.000179	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTA2—liver cancer	2.16e-05	0.000179	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TERT—liver cancer	2.13e-05	0.000176	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CPT1B—liver cancer	2.1e-05	0.000174	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GLUL—liver cancer	2.1e-05	0.000174	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTA1—liver cancer	2.09e-05	0.000173	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NAT2—liver cancer	2.06e-05	0.000171	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CD—liver cancer	2.06e-05	0.000171	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—liver cancer	2.06e-05	0.00017	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—ALB—liver cancer	2.04e-05	0.000169	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NR1H4—liver cancer	2.02e-05	0.000167	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—liver cancer	2.02e-05	0.000167	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK14—liver cancer	2.01e-05	0.000167	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CD—liver cancer	2e-05	0.000166	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTA4—liver cancer	1.99e-05	0.000165	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—TGFB1—liver cancer	1.99e-05	0.000165	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTA3—liver cancer	1.99e-05	0.000165	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.99e-05	0.000164	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ALDOB—liver cancer	1.98e-05	0.000164	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ALB—liver cancer	1.98e-05	0.000164	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—F2—liver cancer	1.95e-05	0.000162	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.95e-05	0.000161	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KDR—liver cancer	1.95e-05	0.000161	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTA2—liver cancer	1.94e-05	0.000161	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK14—liver cancer	1.93e-05	0.00016	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ESR1—liver cancer	1.9e-05	0.000157	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CRABP1—liver cancer	1.89e-05	0.000156	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—PPARA—liver cancer	1.89e-05	0.000156	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—F2—liver cancer	1.87e-05	0.000155	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTA1—liver cancer	1.87e-05	0.000155	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CG—liver cancer	1.87e-05	0.000155	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NAT2—liver cancer	1.85e-05	0.000153	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTA4—liver cancer	1.82e-05	0.00015	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CB—liver cancer	1.8e-05	0.000149	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APC—liver cancer	1.79e-05	0.000149	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CG—liver cancer	1.79e-05	0.000149	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.78e-05	0.000148	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALDOB—liver cancer	1.78e-05	0.000147	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	1.78e-05	0.000147	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTA2—liver cancer	1.77e-05	0.000147	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CB—liver cancer	1.74e-05	0.000144	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTA1—liver cancer	1.71e-05	0.000141	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.7e-05	0.000141	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CRABP1—liver cancer	1.7e-05	0.00014	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	1.69e-05	0.00014	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NAT2—liver cancer	1.69e-05	0.00014	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—BRAF—liver cancer	1.69e-05	0.00014	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HPGDS—liver cancer	1.65e-05	0.000137	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CD—liver cancer	1.64e-05	0.000136	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.64e-05	0.000136	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	1.62e-05	0.000135	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SERPINE1—liver cancer	1.62e-05	0.000134	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALDOB—liver cancer	1.62e-05	0.000134	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CD—liver cancer	1.58e-05	0.000131	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SERPINE1—liver cancer	1.56e-05	0.000129	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CRABP1—liver cancer	1.55e-05	0.000128	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.53e-05	0.000126	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.49e-05	0.000124	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HPGDS—liver cancer	1.48e-05	0.000123	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.47e-05	0.000122	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PSMD10—liver cancer	1.47e-05	0.000122	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PSMA4—liver cancer	1.47e-05	0.000122	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—RAF1—liver cancer	1.47e-05	0.000121	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GOT2—liver cancer	1.43e-05	0.000118	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CB—liver cancer	1.43e-05	0.000118	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RAF1—liver cancer	1.41e-05	0.000117	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.39e-05	0.000115	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—liver cancer	1.38e-05	0.000114	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MTOR—liver cancer	1.37e-05	0.000114	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CB—liver cancer	1.37e-05	0.000114	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HPGDS—liver cancer	1.35e-05	0.000112	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP2E1—liver cancer	1.35e-05	0.000111	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.34e-05	0.000111	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.34e-05	0.000111	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.32e-05	0.00011	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PSMA4—liver cancer	1.32e-05	0.000109	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PSMD10—liver cancer	1.32e-05	0.000109	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—liver cancer	1.31e-05	0.000109	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.3e-05	0.000108	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1B—liver cancer	1.29e-05	0.000107	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GOT2—liver cancer	1.28e-05	0.000106	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—RAF1—liver cancer	1.27e-05	0.000105	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CASP3—liver cancer	1.26e-05	0.000105	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—liver cancer	1.26e-05	0.000105	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYCS—liver cancer	1.26e-05	0.000104	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GGT1—liver cancer	1.24e-05	0.000102	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GOT1—liver cancer	1.24e-05	0.000102	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—liver cancer	1.23e-05	0.000102	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JUN—liver cancer	1.23e-05	0.000102	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.22e-05	0.000101	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CTNNB1—liver cancer	1.22e-05	0.000101	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP2E1—liver cancer	1.21e-05	0.0001	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.21e-05	0.0001	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PSMA4—liver cancer	1.2e-05	9.97e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PSMD10—liver cancer	1.2e-05	9.97e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—liver cancer	1.19e-05	9.89e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDKN1A—liver cancer	1.19e-05	9.85e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GOT2—liver cancer	1.17e-05	9.7e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.17e-05	9.68e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK8—liver cancer	1.16e-05	9.62e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYCS—liver cancer	1.13e-05	9.35e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—liver cancer	1.12e-05	9.24e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTP1—liver cancer	1.11e-05	9.19e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GOT1—liver cancer	1.11e-05	9.18e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GGT1—liver cancer	1.11e-05	9.18e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP2E1—liver cancer	1.1e-05	9.12e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—liver cancer	1.1e-05	9.08e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HMOX1—liver cancer	1.09e-05	9.06e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.07e-05	8.83e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—liver cancer	1.06e-05	8.8e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—liver cancer	1.06e-05	8.79e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYCS—liver cancer	1.03e-05	8.53e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TGFB1—liver cancer	1.03e-05	8.49e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTM1—liver cancer	1.02e-05	8.44e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GOT1—liver cancer	1.01e-05	8.37e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GGT1—liver cancer	1.01e-05	8.37e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTP1—liver cancer	9.96e-06	8.25e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MYC—liver cancer	9.87e-06	8.17e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFB1—liver cancer	9.85e-06	8.15e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HMOX1—liver cancer	9.82e-06	8.13e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP1A1—liver cancer	9.67e-06	8e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—liver cancer	9.49e-06	7.86e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTM1—liver cancer	9.15e-06	7.58e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—liver cancer	9.12e-06	7.55e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTP1—liver cancer	9.08e-06	7.52e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MTHFR—liver cancer	9.01e-06	7.46e-05	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—liver cancer	8.96e-06	7.42e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HMOX1—liver cancer	8.96e-06	7.41e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARA—liver cancer	8.84e-06	7.32e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—liver cancer	8.72e-06	7.22e-05	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—liver cancer	8.69e-06	7.19e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP1A1—liver cancer	8.68e-06	7.18e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—liver cancer	8.44e-06	6.99e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—liver cancer	8.38e-06	6.94e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTM1—liver cancer	8.35e-06	6.91e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—liver cancer	8.11e-06	6.71e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MTHFR—liver cancer	8.09e-06	6.7e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—liver cancer	8.07e-06	6.68e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.94e-06	6.57e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARA—liver cancer	7.94e-06	6.57e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP1A1—liver cancer	7.91e-06	6.55e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—liver cancer	7.75e-06	6.42e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CG—liver cancer	7.57e-06	6.27e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—liver cancer	7.42e-06	6.14e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MTHFR—liver cancer	7.38e-06	6.11e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARG—liver cancer	7.31e-06	6.05e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARA—liver cancer	7.24e-06	5.99e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.13e-06	5.9e-05	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—liver cancer	7.13e-06	5.9e-05	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—liver cancer	6.85e-06	5.67e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CG—liver cancer	6.8e-06	5.63e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CD—liver cancer	6.66e-06	5.51e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARG—liver cancer	6.56e-06	5.43e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.5e-06	5.38e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CG—liver cancer	6.2e-06	5.13e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARG—liver cancer	5.98e-06	4.95e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CD—liver cancer	5.97e-06	4.95e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ALB—liver cancer	5.9e-06	4.88e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CB—liver cancer	5.8e-06	4.8e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CD—liver cancer	5.45e-06	4.51e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ALB—liver cancer	5.38e-06	4.45e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CB—liver cancer	5.21e-06	4.31e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CB—liver cancer	4.75e-06	3.93e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—liver cancer	3.54e-06	2.93e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—liver cancer	3.17e-06	2.63e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—liver cancer	2.89e-06	2.4e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—liver cancer	2.89e-06	2.39e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—liver cancer	2.59e-06	2.15e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—liver cancer	2.36e-06	1.96e-05	CbGpPWpGaD
